On December 28th, 2021 the FDA authorized, for the first time, outpatient use of COVID-19 convalescent plasma. The announcement letter can be found here. 

As COVID-19 surges in the United States and around the world, we want to reiterate the following statements:

  •  Sign the petition: Open letter to the FDA to permit access to COVID-19 convalescent plasma for outpatient use. The letter with the first 90 signatories can be found here.
  • Convalescent plasma remains under EUA in the United States.
  • Convalescent plasma is more effective when used early in treatment, research highlighting this can be found here and here
  • Local convalescent plasma is preferable to distantly sourced convalescent plasma.